Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jamey Weichert
University of Wisconsin Madison, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Archeus Technologies
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
An outside activity has a nexus with an individual's research activities if the outside activity arises from, relies upon or is related to the academic expertise that qualifies that individual to participate in federally funded research or human subjects research. The Institution has reasonably determined that the significant financial interest could directly and significantly affect the design, conduct, or reporting of the PHS-funded research and so requires management.
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies
PROJECT NARRATIVE We are developing a new approach, representing a dramatic shift in the treatment of metastatic cancer, utilizing immune responses to recognize and destroy cancer (known as immunotherapy) in combination with low-dose radiation therapy, which substantially improves the anti-tumor potency of the immunotherapy regimens we are creating. We have shown that low-dose radiation, if delivered to all sites of cancer in a mouse, enables our combination immunotherapy approach to destroy tumor throughout the mouse; however there are great difficulties in delivering conventional radiotherapy to all cancer sites in patients when cancer has spread to many sites. Instead, we are giving molecular targeted radiotherapy that can be injected into a patient?s vein and can go throughout the body to preferentially deliver the radiation to tumors wherever they are located. We will test this combined approach in order to determine which combinations should be most beneficial in patients with metastatic cancer.
Filed on October 03, 2018.
Tell us what you know about Jamey Weichert's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Jamey Weichert filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Jamey Weichert | University of Wisconsin Madison | Conflict of Interest | Archeus Technologies | $100,000 - $149,999 |
| Jamey Weichert | University of Wisconsin Madison | Conflict of Interest | Archeus Technologies | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.